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 Becoming is not about arriving somewhere or achieving a certain aim. I see it instead as 
forward motion, a means of evolving, a way to reach continuously toward a better self. The 
journey does not end.  
Michelle Obama 
  
  
ABSTRACT 
Critical illness, defined as a life-threatening organ failure, entails an extreme stress that 
results in a pathophysiology of its own. The abnormal metabolism of these patients causes a 
severe muscle wasting that is poorly understood. One hypothesis is that the muscle is 
sacrificed to provide the body with key metabolic substrates, such as the amino acid 
glutamine.  
Both low and high plasma glutamine concentrations at Intensive Care Unit (ICU) admission 
are associated with a higher mortality. However, the mechanisms behind these associations 
are unknown. It has been suggested that there is an increased demand for glutamine in critical 
illness and that its availability is crucial for proper function of the immune system and the 
intestine. Hence, several intervention studies on glutamine supplementation in the ICU have 
been conducted. However, design and included patients varies widely and thus the results are 
heterogenous and problematic to compare. In order to explore the hypothesis that low plasma 
glutamine concentration in critical illness represents a shortage that may motivate glutamine 
supplementation, glutamine kinetics in these patients needs to be characterized. 
The first step was to establish and validate a bolus injection method to measure glutamine 
endogenous rate of appearance (endoRa) for studying endogenous glutamine production in 
the ICU setting. When this method was applied, a positive correlation was detected, where 
35% of variability in plasma glutamine concentration could be related to endoRa during 
critical illness. 
The second part of the thesis consists of observational studies on plasma glutamine 
concentrations in connection to outcome and specific diagnoses. In the post ICU period, 
plasma glutamine concentration was within the reference range and was not related to 
mortality.  
In liver failure, regardless of aetiology, severity and course of illness, a high plasma 
glutamine concentration was a common finding, although most frequent in patients with 
acute fulminant and acute-on-chronic liver failure. There was a positive correlation between 
the severity of liver failure and plasma glutamine concentration. 
Admission hyperglutaminemia (≥930 µmol/L) was an independent predictor for high 
mortality. A majority of the hyperglutaminemic patients had a liver condition, although 
hyperglutaminemia was also observed in patients without signs of liver affection. 
The role of glutamine in critical illness is still not settled. Our observations give no indication 
that a high plasma glutamine per se is toxic. The finding that low plasma concentrations 
correlates with a lower endogenous production keeps the possibility open that there is a 
cohort of critically ill patients with too low glutamine availability, who would benefit from 
exogenous glutamine supplementation. The ultimate question if plasma glutamine 
concentration is just a biomarker or if it also gives signal of a deficit and/or an impaired 
handling of glutamine is still pending. Therefore, glutamine kinetics in critical illness needs 
to be further clarified.   
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1 INTRODUCTION 
 
1.1 CRITICAL ILLNESS 
Critical illness is a life-threatening failure in one or more vital organ; heart/cardiovascular 
system, lungs, brain, liver, haematological/coagulation system, or kidneys, resulting in the 
need of intensive care for survival. The patients in the intensive care unit (ICU) are a very 
heterogenous group, ranging from young to elderly patients with or without comorbidities 
and with single or multi organ failure. Most patients in the ICU have respiratory failure in 
need of mechanical ventilation, either solitary or in combination with other organ failures.  
Before the 20th century, critical illness was hardly compatible with life. But with the 
evolvement of modern, highly advanced technique and medical treatments, there is now an 
increased capacity to keep patients alive. The intensive care supports vital functions and buys 
time, giving the body a chance to heal. Still, critical illness entails a high mortality; 20-30% 
within six months for ICU patients in Sweden (1). Critical illness exposes the body to an 
extreme situation, with a pathophysiology of its own and severely deviating physiological 
processes and metabolism. In the acute phase all systems are mobilized in a last attempt to 
survive, this results in high levels of inflammatory mediators and catecholamines, together 
with hemodynamic instability. With intensive care support, a majority of the patients recover 
during this phase. Those that do not, enter a prolonged catabolic phase, often accompanied by 
an increased metabolic rate (2, 3). These processes are sometimes highly maladaptive, 
especially for the patients with a prolonged ICU stay, where it can lead to cachexia, poor 
wound healing and immunosuppression with secondary morbidities and chronic infirmity as a 
result (2-4).  
 
1.2 GLUTAMINE METABOLISM IN HEALTH 
Glutamine (C5H10N2O3) has a molecular weight of 146.14 g/mol and is the most abundant 
free amino acid in the human body, representing 20% of the free amino acid pool in plasma 
and up to 60% in specific tissues. A 70 kg adult has about 70-80 g of free glutamine 
distributed throughout the body (5). It is a non-essential amino acid, meaning that healthy 
individuals can produce all that the body requires. Endogenous glutamine production is 
estimated at a daily rate of the same quantity as the whole-body free glutamine content;  
65-85 g/day in adults, corresponding to 4.5-5.8 µmol/kg/min in a 70 kg subject, and can be 
derived both from de novo synthesis and protein breakdown (6). In addition, the protein in a 
normal diet contains 8-12% glutamine, accounting for an intake of about 10 g glutamine/day 
and, thus, a healthy person will have ready access to glutamine at any given point (7). This is 
fundamental, as this amino acid has several vital functions throughout the body (8). 
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Figure 1. Glutamine synthesis from, and hydrolysis to, glutamate and further hydrolysis to oxoglutarate, which 
in turn enters the citric acid cycle to form energy in the mitochondria. (Adapted with permission (5)) 
The interest in glutamine began with the finding that it is a crucial component for survival 
and proliferation in cell cultures (8). Glutamine can be utilized by several different metabolic 
pathways. It can easily be transformed to glutamate by the enzyme glutaminase (GLS), which 
removes NH3. The reaction is reversible through the endergonic reaction of adding NH3, by 
glutamine synthetase (GS). Nitrogen in the form of free ammonia is neurotoxic, but by 
attaching it to glutamate and form glutamine, safe transport between tissues is enabled. By 
reversing the reaction, the nitrogen can be disposed in liver and kidneys.  
GS and GLS are expressed differently in tissues depending on if they are a main producer or 
consumer of glutamine. Skeletal muscle, liver, adipose tissue, and lungs have a high GS 
activity, whereas leukocytes, enterocytes and renal cells have a high GLS activity. Skeletal 
muscle cells are considered a key producer of glutamine as they have a high export. Thus, the 
muscles provide other tissues with glutamine and the main target is the splanchnic organs.  
White blood cells and enterocytes utilize glutamine as a main energy fuel. In these cells, 
glutamine is converted to glutamate and then oxoglutarate by removal of both NH3-groups. It 
then enters the citric acid cycle in the mitochondria. Glutamine is also a precursor for 
nucleotides and nucleic acids in DNA and RNA synthesis. It is therefore a key substrate, 
supporting high mitotic activity in these tissues. 
In the kidneys, the NH3 from glutamine is exported to the collecting tubule and combined 
with H+ to form NH4
+ in the urine. Due to this possibility to dispose H+, the kidney can 
transform carbonic acid (H2CO3) into bicarbonate (HCO3
-), which is one of the major ways to 
regulate pH in the blood. Additionally, glutamine is a substrate for gluconeogenesis in both 
kidney and liver. 
In the brain glutamine serves as a precursor for glutamate, which is one of the major 
excitatory neurotransmitters. Moreover, glutamine is a substrate for protein synthesis and a 
precursor to glutathione, an antioxidant which protects the body from free radicals, 
preventing oxidative stress and cell damage. 
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1.3 GLUTAMINE AND THE IMMUNE SYSTEM 
The function of glutamine in immune cells has been extensively studied in vitro, in both 
rodent and human cell lines. It has been found to be an important energy substrate, to activate 
intracellular signalling pathways, and to regulate gene expression of several genes. Thereby, 
glutamine has an essential role in cell proliferation and differentiation, tissue repair, and 
pathogen recognition (5) in immune cells. In vitro studies have also shown that glutamine can 
enhance a great variety of important functions such as T-cell proliferation, B-lymphocyte 
differentiation, macrophage phagocytosis, antigen presentation and cytokine production (8, 
9). However, it is unclear how these findings translate to in vivo human immune cells. Firstly, 
the concentration of glutamine in cell cultures is 2-10 mM, which is far from the 
physiological normal plasma concentration of 0.4-0.7 mM. Secondly, a lot of the studies 
showing enhanced function are made on rodent cells and the same concentration-dependent 
enhancement has not always been replicable in human cell lines (10).  
Nevertheless, it cannot be disregarded that a low plasma glutamine concentration may result 
in a partly impaired immune system. A considerable increase in metabolic activity, reflected 
as fractional protein synthesis rate, in circulating leukocytes and mononuclear cells has been 
reported as part of the acute phase response in both human endotoxemic sepsis models and 
ICU patients (11, 12). An activated immune system has a high cell proliferation, energy 
consumption, DNA translation and protein production, all of which consumes glutamine. 
Hence, it is likely that glutamine utilization increases with immune cell activity and that 
glutamine availability is vital.  
 
1.4 GLUTAMINE AND THE INTESTINE 
The gut has a high glutamine uptake, both from intestinal lumen and from blood, indicating it 
as a key nutrient for this tissue. Even though the intestine is continuously provided with 
glutamine from the diet, it still utilizes about 30% of the total endogenously produced 
glutamine (13). Despite this very high influx of glutamine, the concentration of glutamine in 
the intestinal tissue is comparably low, though higher than in plasma. This is due to a high 
activity of glutaminase, which has a very high affinity for its substrate and therefore 
efficiently hydrolyses a large proportion of the available glutamine to glutamate (5). Hence, 
very little enterally provided glutamine reaches the blood stream (14, 15).  
Glutamine serves many purposes in the gut aside from energy substrate. The enterocytes 
constitute one of our most important barriers, and its function is vital in both absorbing 
nutrients while at the same time shutting out unwanted substances and pathogens. As long as 
the microbiota is maintained in the intestinal lumen the symbiosis is beneficial. But, in a 
critically ill patient the barrier may fail, resulting in translocation of microbes and toxin (16, 
17). This can cause a severe sepsis, which is particularly troublesome in patients colonized by 
antibiotic resistant bacteria. The barrier is regulated by a cooperation between the enterocytes, 
tight junction proteins, and submucosal immune cells. The integrity is highly dependent on 
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the constant renewal of the enterocytes, which have a lifespan of 3-5 days only. Glutamine is 
a main component for their proliferation, but also regulates apoptosis and cell survival and 
thus, helps maintaining the crucial balance of cell turnover (13, 18). The tight junction 
proteins seal the paracellular permeability. Their function is also dependent on a constant 
renewal, and presence of glutamine is important in gene expression for maintaining protein 
synthesis in the enterocytes (13). Moreover, inflammatory cytokines increase intestinal 
permeability and in vitro studies suggest that glutamine inhibits production of these cytokines 
(5, 13).  
 
1.5 GLUTAMINE AND THE LIVER 
The liver is a key metabolic organ that serves to maintain homeostasis in many systems. The 
main functions of glutamine in the liver are as a gluconeogenesis substrate and a source of 
ammonia for urea synthesis. Glutamine is a regulator of the urea cycle, where higher 
glutamine concentrations increases urea production (5). Also, uptake of glutamine leads to 
cell swelling through osmosis. It has been suggested that this in turn stimulates anabolic 
processes in the hepatocytes and that, accordingly, reduced intracellular glutamine 
concentrations stimulates catabolic processes and insulin resistance (5, 19).  
The hepatocytes positioned in the proximal sinusoids, where the blood enters from the portal 
vein, have a high uptake of glutamine, and expresses GLS, gluconeogenesis and urea 
synthesis enzymes. On the contrary, the hepatocytes in the distal sinusoids, right before the 
blood exits the liver, express GS instead. This enzyme has a high affinity for ammonia, and 
thereby these cells act as ammonia scavengers, making sure that very little free ammonia 
escapes to the general circulation. Consequently, the liver is both a consumer and a producer 
of glutamine and, although the glutamine synthetizing cells constitutes a much smaller 
proportion (5-7%), there is a net balance between consumption and production in a healthy 
liver (20).  
Glutamine uptake in hepatocytes is mediated through a sodium-dependent transporter, which 
utilizes the Na/K electrochemical gradient across the plasma membrane to maintain an 
intracellular glutamine concentration of 3-7 mmol/L. The transporter has a pH-dependent 
activity, increasing with higher pH (20). Similarly, the activity of GLS increases fast with 
more alkalotic pH (19). Hence, this regulation favours glutamine synthesis in the liver during 
acidosis, which provides glutamine to the kidneys for HCO3
- production (21). Moreover, it is 
important in patients with liver cirrhosis, where urea synthesis is maintained despite an 
impaired hepatocyte function, partly due to a habitual metabolic alkalosis. However, this 
makes the chronic liver disease patient vulnerable to any process resulting in acidosis, such as 
infections and hemodynamic instability, which in turn leads to hyperammonemia. Also, the 
cells expressing GS are reduced with up to 80% in cirrhosis, incapacitating the backup system 
that normally captures excess ammonia (19). Additionally, in patients with cirrhosis and/or 
portal vein thrombosis, blood from the intestine bypasses the liver and is therefore not 
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cleansed from ammonia, adding to increased ammonia concentration in the systemic 
circulation (22). 
In patients with liver failure and hepatic encephalopathy, hyperammonemia is recognized as a 
part of the pathophysiology (23). Ammonia is toxic to nerve cells and the brain lacks an 
efficient urea cycle. Hence, glutamine synthesis in astrocytes is the only path for ammonia 
detoxication in the brain. The excess ammonia will lead to excessive glutamine synthesis in 
astrocytes, which in turn leads to osmotic cell swelling and is believed to contribute to brain 
edema and increased intracranial pressure (24).  
 
1.6 GLUTAMINE METABOLISM IN CRITICAL ILLNESS 
When the human body is exposed to a major catabolic condition such as intense and 
prolonged exercise, cancer, major surgery, or critical illness, there is a presumed increased 
demand for glutamine (5). The stress of critical illness results in elevated cortisol levels, 
which in turn stimulates GS in skeletal muscle (25). Subsequently, there is an enhanced 
glutamine export from skeletal muscles, that remains constant over the duration of critical 
illness (26). Initially glutamine release from skeletal muscle exceeds the intracellular 
production, and as a result a general depletion of free glutamine in muscle is seen in critically 
ill patients (7). After a period of adaption, the endogenous production of glutamine can keep 
up with the demand, at the cost of substantial muscle protein wasting. Some patients admitted 
to the ICU have initial low plasma glutamine concentrations, which seems to be sustained 
over time (27-30). Although there are few reports on plasma glutamine concentrations over 
time in ICU patients (26-33). Because of the low concentrations in plasma as well as muscle, 
it has even been suggested that glutamine is “conditionally essential” in these patients (21).  
The lungs are also reported to be an important glutamine provider in critical illness. Unlike 
skeletal muscle, the lungs do not have any glutamine storage, and in health they have a net 
balance of glutamine. But during sepsis and burn injury, GS activity is significantly 
increased, and pulmonary glutamine release is reported to account for about 20% of the total 
glutamine production (34, 35). However, these reports are based on measurements of blood 
flow and arteriovenous difference in glutamine which both have considerable limitations in 
accuracy. Hence, the significance of the lungs as a glutamine provider is still unclear.  
There are several rationales for a higher glutamine demand in critical illness. Patients 
admitted to critical care often have severe infections and sepsis. This increases the activity of 
the immune system, consuming glutamine both for energy, protein synthesis and DNA 
synthesis as the cells multiply. Also, an activated immune system and inflammation will lead 
to more reactive oxygen species as it is part of the defence against pathogens. This leads to a 
high oxidative stress that increases the utilization of glutamine to produce glutathione and 
sustain redox balance. ICU patients have been demonstrated to have low total glutathione 
concentration in whole blood (36, 37).  
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Figure 2. Glutamine production and utilization in health (A) versus critical illness (B). Blue/filled arrows 
indicate tissues that have high glutamine synthetase (GS) activity and thus produce glutamine; white arrows 
indicate tissues with glutaminase (GLS) activity, which consume glutamine. In health there is an equilibrium in 
plasma and tissues, which is constantly maintained primarily by the liver and skeletal muscles. Cells of the 
immune system are dependent on glucose and glutamine provision in health, and even so more during severe 
illness. The gut is also a major site of glutamine consumption in health, whereas the acute phase of critical 
illness is associated with an impairment of enterocyte glutamine uptake. Additionally, the brain and the kidneys 
only express GLS, and hence mainly depend on plasma glutamine availability. The liver switches role from a 
major glutamine producer (A) to a major consumer (B) to sustain gluconeogenesis and increased protein 
synthesis. The lungs express both GS and GLS enzymes, and switch from a net glutamine balance to a possible 
glutamine producer in critical illness. Subsequently, the whole body relies mostly on the skeletal muscle to 
maintain glutamine concentration in critical illness, often accompanied by problematic muscle wasting. The 
adipose tissue expresses both GS and GLS enzymes, and hence can produce and consume glutamine in both 
situations. (Adapted with permission (5)) 
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Moreover, it is common that the patients are acidotic, forcing the kidneys to produce more 
HCO3-. Acidosis leads to hypotension through vasodilation, impaired coagulation and 
declined enzyme function, so the ability to balance pH is crucial for these patients. Acidosis 
increases the uptake and catabolism of glutamine in the proximal tubule of the kidney (38). 
However, there are other pathways for pH regulation and hypoglutaminemia has not been 
related to acidosis. 
Furthermore, the liver also exhibits an elevated glutamine uptake during critical illness in 
order to support the increased protein and glutathione synthesis and gluconeogenesis (19). In 
a rat endotoxemic sepsis model, the hepatic glutamine uptake increased nearly tenfold (39). 
On the contrary, ischemia, sepsis and severe inflammation seems to significantly reduce 
intestinal glutamine uptake from plasma in the acute phase (40-42). 
 
1.6.1 Muscle wasting and glutamine depletion 
Most critically ill patients can meet an increased glutamine demand and sustain plasma 
glutamine concentrations. However, this entails a general depletion of protein and free 
glutamine in skeletal muscle. The intracellular free glutamine concentration in muscle is 
reduced by 70-80% in ICU patients (25, 43, 44). This profound drop seems to be part of the 
early acute phase response. Stress hormone induction of outward transport systems and/or 
electrical transmembrane potential changes have been suggested mechanisms that result in 
this rapid glutamine mobilization (7).  
There is little correlation between plasma concentration and skeletal muscle concentration of 
glutamine (29, 45, 46). In elective post-op patients the glutamine concentration drops in 
muscle, whereas it remains stable in plasma (46). The intracellular glutamine depletion 
develops during the immediate postoperative period and the lowest concentration is seen in 
the first 2-4 days. The concentration is then restored slowly over 2-4 weeks (47). Parenteral 
glutamine supplementation in the postoperative period prevents this reduction in skeletal 
muscle, but if supplementation stops the reduction is only postponed (46).  
In ICU patients the concentration in muscle drops extensively, while the plasma 
concentration is variable and has a less remarkable decrease (29, 45). This can be illustrated 
by the ratio of glutamine concentration in plasma compared to intracellular concentration in 
skeletal muscle. In healthy subjects this ratio is 1:30 whereas the critically ill have a ratio of 
1:5-1:10 (45). This profound depletion takes a long time to restore and is not readily 
influenced by supplementation (29). One reason for that could be the net efflux of glutamine 
from muscle that might be hard to turn around as long as there is an increased demand in 
other, more prioritized tissues. Another theory is that muscle cells are constructed to be self-
supporting in glutamine and do not have a system adapted to a large glutamine uptake, as 
only 25% of the intramuscular glutamine pool is derived from extracellular space normally 
(7). 
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The glutamine balance in skeletal muscle is complex and controlled by several different 
pathways. Elevated plasma levels of cortisol (48, 49) and tumour necrosis factor alpha, and 
low intracellular glutamine concentrations have been shown to stimulate GS activity (7). 
Also, protein breakdown in skeletal muscle, which results in release of free glutamine, is 
considerably increased during critical illness. On the other hand, catecholamines suppress GS 
so the proportions of stress hormones in the patient could affect glutamine balance (7).  
In patients with severe burn injury, a distinct cohort with excessive hypermetabolism and 
severe muscle wasting over long time, a threefold increase in muscle glutamine synthesis is 
reported. However, the intracellular utilization was increased to the same extent and the 
export rate from muscle was increased, resulting in a net negative balance (25). Moreover, 
after two weeks in intensive care, glutamine de novo synthesis is reported to be reduced in 
burn patients resulting in a decreased glutamine availability (43).  
The high efflux of glutamine from skeletal muscle has been shown to be sustained over at 
least the initial two weeks of critical illness (26). During the initial phase of critical illness, up 
to 10% of the muscle protein is wasted per week (50). In patients with a prolonged phase of 
critical illness this continuous protein breakdown leads to a general muscle depletion (28, 50). 
The muscle wasting results in a weakness and physical disability that can be sustained for 
years in ICU survivors (50).  
It has been suggested that patients with an initial higher muscle mass can sustain glutamine 
export, and therefore are the selected survivors for long-term critical illness. It is known that 
patients with overweight and moderate obesity (BMI 25-40) have a lower mortality and a 
longer length of stay in the ICU than patients with normal weight (BMI 18.5-25) (51). The 
reason for this is unknown, but a possible explanation is that at least some of these patients 
have a higher muscle mass, which can sustain a high glutamine production and thereby 
contributes to their survival (52). 
 
1.6.2 Hypoglutaminemia 
The prevalence of low plasma glutamine (<400-420 µmol/L) (36, 53) at ICU admission 
ranges from 31-65% (27, 36, 53-58). Especially, critically ill patients with multitrauma (27, 
55, 57), major burn injury (59, 60) and severe sepsis (31, 57) have been linked to 
hypoglutaminemia. Low plasma glutamine concentration has been shown to be associated 
with a higher mortality, both at admission and during the course of illness (31, 36, 53).  
According to several reports there is no significant correlation between hypoglutaminemia 
and severity of illness, expressed by conventional risk scoring Acute Physiology And 
Chronic Health Evaluation (APACHE II) (31, 36, 53). Also, adding low plasma glutamine 
concentration to risk scoring gives an improved mortality prediction. However, other studies 
with a very high prevalence of hypoglutaminemia (58% and 65%) have reported a correlation 
between low plasma glutamine and high risk scoring, in a mixed population of expected long-
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stayers in South Africa (APACHE II) (57) and in mixed consecutive patients in Holland 
(APACHE IV) (56).  
The flow of glutamine between different compartments varies and a low concentration in 
plasma is therefore not necessarily an indication of a general deficiency. Glutamine in plasma 
is only a small proportion of the whole-body free glutamine pool, as intracellular 
concentrations are much higher in several tissues (61-63). Also, the intracellular changes in 
glutamine concentration during critical illness follow a different pattern than plasma; skeletal 
muscle has a more general and profound drop than plasma, whereas liver and intestine tend to 
follow the same trend as plasma concentration (5, 64). Nevertheless, the plasma pool 
represents the glutamine immediately available for the immune system and other cells that 
rely upon glutamine supply from other tissues.  
The theory that a low plasma glutamine concentration leads to an impaired immune system is 
appealing, but it is almost entirely based on cell culture studies and has little scientific support 
in vivo. Supranormal intracellular glutamine concentrations have been reported in 
polymorphonuclear neutrophils of trauma patients on day one. But from day five a persisting 
30% decrease was found instead. Although 40% of the patients had hypoglutaminemia, the 
intracellular glutamine concentration in the neutrophils followed the same pattern in all 
included patients, regardless of plasma glutamine (58).  
As hypoglutaminemia occurs in the acute phase of critical illness, when de novo synthesis 
and muscle release is accelerated, the low plasma concentration is probably a result of an 
acutely intensified utilization. However, ICU patients are often elderly and accompanied by 
comorbidities, chronic disease and malnutrition, all of which are also likely to decrease 
plasma glutamine concentrations (53, 65, 66). 
Although an increased utilization is plausible, the pathophysiology resulting in 
hypoglutaminemia is largely unknown. Contributing factors include increased hepatic uptake, 
amino acid loss by urine in trauma patients, continuous renal replacement therapy (67), 
insufficient nutrition, blood loss and dilution secondary to resuscitation with crystalline fluids 
(68). A low plasma glutamine has been related to inflammation and active infection (56), 
correlating with elevated C-reactive protein (CRP) and interleukin 6 (IL6) levels (31, 54, 57, 
69). Moreover, low plasma glutamine has been reported to be associated with low albumin 
(31, 53), which can be a result of both severe inflammation and malnutrition. 
ICU long-stayers that develop chronic critical illness syndrome have elevated CRP and IL6 
levels, immunosuppression and protein catabolism with cachexia (4), all of which can be 
connected to hypoglutaminemia. 
A persisting insufficient glutamine availability may affect numerous metabolic pathways 
regulating cell survival and proliferation (18, 70), affecting wound healing, the intestinal 
barrier and the immune system (5). Also, based on in vitro studies, intracellular glutamine 
depletion promotes cell dehydration, which may further support the catabolic state and 
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contribute to insulin resistance (19, 71). A persistent low plasma glutamine during the course 
of critical illness has been reported to be associated with more infections and increased length 
of stay (27). 
 
1.6.3 Hyperglutaminemia 
High plasma glutamine concentrations are less studied, but in available reports 5-15% of 
critically ill patients have hyperglutaminemia at ICU admission (36, 53, 54, 57, 72). The cut-
off used is either >700 µmol/L, which is the upper limit for normal value in healthy 
individuals, or >930 µmol/L, which is the cut-off for increased mortality found in ICU 
patients (36). Hyperglutaminemia is also associated with an unfavourable outcome at 
admission (36), as well as during the course of illness (31). The underlying mechanism is 
unknown, but there is an overrepresentation of patients with liver failure in this group and 
higher plasma glutamine concentration is correlated with elevated alanine transaminase 
(ALT), aspartate transaminase (AST) and bilirubin concentrations (31, 57). Hence, a 
decreased hepatic uptake of glutamine due to substantial liver damage may be a part of the 
pathophysiology. High plasma glutamine concentration is a characteristic of patients with 
acute fulminant liver failure (73), which is therefore considered a contraindication for 
glutamine substitution.  
Plasma creatinine kinase, as an indicator of cell damage, has been reported to be higher in the 
hyperglutaminemia group at admission (53), but not after thirteen days in the ICU (31). In 
theory, considerable cell damage could give an acute raise in plasma glutamine concentration, 
as intracellular glutamine concentration is much higher than in plasma (61-63). 
A proposed pathophysiology contributing to hyperglutaminemia in liver failure is an 
excessive utilization of the backup system for ammonia detoxication. When urea synthesis in 
the liver is impaired, increased ammonia concentration in the systemic circulation will 
stimulate GS, primarily in skeletal muscles. A possible fate for the resulting glutamine is 
oxidation in enterocytes, which in turn will produce two ammonia molecules leading to a 
vicious circle of increasing glutamine and ammonia production (74). Whereas high levels of 
ammonia lead to excess glutamine synthesis in the brain, which contributes to brain edema, 
isolated hyperglutaminemia does not seem to have the same effect. 
 
1.7 GLUTAMINE SUPPLEMENTATION  
Proteins in enteral nutrition normally contain 7-8% glutamine, similar to a normal diet. 
Parenteral nutrition, however, does not, due to the instability of free glutamine in aqueous 
solution. It has, therefore, been suggested to supplement parenteral nutrition with a separate 
alanyl-glutamine or glycyl-glutamine dipeptide solution, in order to provide the patients with 
a normally composed nutrition.  
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As hypoglutaminemia at ICU admission is reported to be associated with a higher mortality 
in critical illness (36, 53), a hypothesis was raised that glutamine supplementation could 
normalize plasma glutamine concentration, thereby resulting in a beneficial effect. However, 
very few studies on glutamine supplementation have included plasma glutamine 
concentrations, and no study has shown a statistical connection between a change in plasma 
concentrations and the beneficial effect. Instead, all patients have been included and grouped 
by other criteria than glutamine concentration. As glutamine has been considered non-toxic, it 
has still been thought reasonable to provide supplementation to all intensive care unit 
patients, given the potential benefits. 
An intravenous glutamine dose will have a more pronounced effect on plasma concentration 
as compared to the same dose given enterally (14, 75). The dose for parenteral glutamine 
supplementation used in intervention studies varies between 0.2-0.5 g/kg/24 , and has been 
shown to adequately restore plasma concentrations to the normal range (29, 76).  
In a small group of ICU patients, 0.35 g glutamine/kg was given for four hours, 
corresponding to 2 g/kg/24 hours. The dipeptide was hydrolysed quickly, and plasma 
glutamine concentrations increased immediately to supranormal levels (1000-1200 µmol/L), 
but dropped back to baseline within eight hours after administration was stopped. No adverse 
effects were reported, despite the high dose and corresponding high plasma concentrations of 
glutamine (75). Similarly, a dose corresponding to 0.9 g/kg/24h given for four hours to cancer 
patients with normal plasma glutamine prior to surgery, also increased plasma glutamine 
>1000 µmol/L (14). When escalating doses of 0 (control), 0.28, 0.57 or 0.86 g of 
glutamine/kg/24h were given for five days to four groups of ICU patients, plasma 
concentrations increased in a dose-dependent way. The three groups receiving glutamine 
supplementation achieved normal plasma glutamine concentration within one day, and some 
patients in the group receiving the highest dose became hyperglutaminemic, whereas the 
control group stayed hypoglutaminemic (29).  
Contrariwise, in trauma patients with high prevalence of hypoglutaminemia (60%), glutamine 
supplementation of 0.35 g/kg/24 hours for five days did not affect plasma concentration after 
the end of supplementation (27). However, as samples were obtained after supplementation 
was discontinued and plasma concentration drops back to baseline rapidly, these results are 
inconclusive. 
If the dipeptide is given enterally it is hydrolysed similarly, but the effect on plasma 
glutamine concentration is modest (77). Considering the high use of glutamine in enterocytes, 
this is likely an effect of first-pass metabolism. As soon as the administration is discontinued 
the plasma concentration will drop back to preadministration levels, in the same way as for 
the intravenous substitution. The different routes of administration will clearly result in 
different distributions.  
The Scandinavian Glutamine Trial, randomizing 418 ICU patients with full nutrition to either 
parenteral glutamine (0.28 g/kg/24h) or placebo, showed a 29% reduction in ICU mortality in 
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the intervention group (78). Several meta-analyses conclude that parenteral glutamine 
supplementation reduces infectious complications, mechanical ventilation duration, hospital 
length of stay and hospital mortality (79, 80). However, the effects of enteral administration 
of extra glutamine is not as convincing (81). Possibly, the different metabolic paths give rise 
to different effects, because only a limited extent of the glutamine from enteral administration 
reaches tissues where a possible beneficial effect emerges. 
Previously, addition of parenteral glutamine was advised to all ICU patients on parenteral 
nutrition (82). However, current guidelines advice against parenteral supplementation of 
glutamine in the ICU and only recommend addition of enteral glutamine to patients with 
major burns or trauma (83). The reasons for this will be discussed in the next section. 
 
1.8 IMMUNONUTRITION AND CONTROVERSY ON GLUTAMINE 
SUPPLEMENTATION 
Immunonutrition is based the concept that certain nutrients are considered to activate and/or 
modulate the immune system. Several nutrients are included such as glutamine, arginine, 
omega-3 fatty acids, nucleotides, selenium, and vitamins A, C and E. The reasoning for 
glutamine in the immunonutrition context is much the same as for glutamine supplementation 
in critical illness; positive effects on the immune system, the redox balance, tissue 
metabolism and cell survival (71, 84). The aim is to give high doses of these nutrients, not to 
supplement a deficit, but to induce pharmacological effects (85). This idea is to most part 
funded on cell culture and animal studies (86) and attempts to translate it into the clinical 
setting in critically ill patients have not had the results anticipated. 
With the REDOX study came an alarming report that glutamine might be toxic (72). In this 
trial 1223 ICU patients were randomized to four groups; placebo, glutamine, antioxidants 
(selenium, zinc, beta carotene, vitamin C and E) or glutamine and antioxidants combined. 
The glutamine dose was high; 0.35g/kg intravenously plus 30 g enterally. For a 70 kg patient 
this means 54.5 g/day compared to about 21 g/day in the majority of earlier studies on 
glutamine supplementation. The enteral dose was administered even if the patient did not 
tolerate enteral nutrition, as it was separated from nutrition. The rationale behind this was that 
using both routes of administration would give positive results in the gastrointestinal system 
as well as systemically and that a higher dose was even more likely to give beneficial results. 
In a pilot pre-study, the dosage used gave the best effect on plasma concentrations without 
any reported adverse effects (87). However, the study result was the opposite, patients who 
received glutamine had a significantly higher six months mortality compared to the control 
group. They also had a longer length of stay, both in the ICU and in the hospital.  
The studied patient group was severely ill with two or more organ failures and a majority was 
in shock, most previous studies have excluded these patients. Plasma glutamine 
concentrations were only measured in a small subgroup of patients and found to be in accord 
with earlier report of ICU patients, both at baseline and at day 4 and 7 of treatment. A 
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majority of patients were within the normal range and 30% were hypoglutaminemic. The 
patients that received glutamine showed a higher frequency of elevated urea levels. This 
could reflect a high metabolic demand on liver and kidneys, from the highly unbalanced 
supply of amino acids and possible nitrogen overload, as the given nutrition was hypocaloric, 
about 900 kcal/day, whereas the total nitrogen intake was high.  
The SIGNET study, randomizing 502 ICU patients with at least 50% parenteral nutrition to 
get addition of glutamine (0.25-0.3 g/kg/24h), selenium, both or neither, showed no 
conclusive results (88). However, the patients were withdrawn from the study when enteral 
nutrition surpassed 50% and the intervention was limited to seven days, which meant that the 
number of patients in the study decreased considerably over time. Moreover, the glutamine 
was mixed with the parenteral nutrition, of which the administration was diminished over 
time and thus, the actual dose administered was not possible to deduce.  
With enteral administration, the METAPLUS trial randomizing 301 ICU patients to get high 
protein enteral nutrition with or without immunonutrients (glutamine (0.28 g/kg/24h), omega-
3 fatty acids, selenium, zinc and vitamins C and E), resulted in a higher six months mortality 
in medical patients in the immunonutrition group (30). This was, however, not related to 
glutamine concentrations, but rather to concentrations of the omega-3-fatty acids (89). 
Similarly, a study giving omega-3 fatty acids, gamma-linolenic acid and antioxidants (zinc, 
selenium, vitamins C and E, beta-carotene, taurine and carnitine) also resulted in a higher 60 
days mortality in the treatment group, although glutamine was not included (90). It has been 
suggested that this combination of nutrients might block the possible beneficial effects of 
each other (91). 
A study on the enteral nutrition Intestamin® randomized 55 ICU patients to either early 
enteral administration of Intestamin® (30 g glutamine, tributyrin, vitamins C and E, 
selenium, zinc) and Reconvan® (10 g glutamine,  arginine, omega-3 fatty acids) or a control 
supplement and Fresubin® original. The calorie intake was the same, but the control nutrition 
had much less protein content (38 g versus 98 g). The study was originally planned to include 
344 patients, but an interim analysis of the first 50 patients showed significant beneficial 
results and enrolment was, therefore suspended at this point, which limits the value of the 
study. The intervention group showed a faster improvement in organ dysfunction, represented 
by a significant reduction in delta SOFA score, which was the primary endpoint (92). It is 
possible that these results are attributable to the protein content, which is closer to current 
recommendations in the intervention group. However, the EAT-ICU trial with a similar 
difference in protein intake between intervention and control group, without glutamine, 
reported no difference in any outcome, including rate of organ failures (93). 
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Study Patients APACHE II 
Median (IQR) 
or Mean ±SD 
SOFA 
Median (IQR) 
or Mean ±SD 
Duration of 
intervention 
Route of 
administration 
Glutamine dose 
Scandinavian 
glutamine trial 
(78) 
Stabilized 
patients within 
72 h of 
admission, 
receiving 
≥80% of full 
nutrition 
21 (18-26) 9 (7-10) Throughout 
ICU stay, 
median  
9 days 
Parenteral 0.28 g/kg/24h 
Redox (72) Mechanical 
ventilation and 
≥2 organ 
failures, within 
24 h of 
admission 
26.6 ±7.6 8.5±2.8 Throughout 
ICU stay, 
median  
8 days 
Parenteral + 
enteral 
0.6-0.8 g/kg/24h 
Signet (88) Patients 
requiring 
≥50% 
parenteral 
nutrition 
20 (16-25) 5 (3-8) Max 7 days, 
median  
5 days 
Parenteral 0.25-0.3 
g/kg/24h* 
Metaplus (30) Mechanically 
ventilated, 
requiring 
enteral 
nutrition 
within 2 days 
after ICU 
admission and 
for >3 days 
22 ±8.5 8 (7-10) Max 28 days, 
median  
12 days 
Enteral 0.28 g/kg/24h 
Intestamin 
study (92) 
Infection, ≥1 
organ failure 
and expected 
ICU stay >3 
days and 
enteral 
nutrition > 5 
days 
14.0 ±5.5 7.3 ±2.1 Max 10 days Enteral 0.56 g/kg/24h 
Table 1. This table summarizes the heterogeneity seen in conducted trials on glutamine supplementation. Patient 
cohorts and interventions varies greatly. Although only a few studies are presented here, this is representative of 
the collected studies made on glutamine supplementation, which makes them very hard to compare. 
*Intended dose, as the parenteral nutrition was diminished over time, the administered dose was lower. 
The available studies on glutamine supplementation have different endpoints, routes of 
administration, doses, and purposes to give the supplementation (Table 1). In addition, 
plasma glutamine has most often not been measured and patients with a potential deficit are 
randomly mixed up among patients with normal or possibly high glutamine concentrations. 
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This will, naturally, give very variable results depending on the case mix of a certain study. In 
the end the original hypothesis has never been tested: Do some critically ill patients have a 
glutamine deficiency, and will this group benefit from supplementation? 
Most importantly, though, the patients included vary decidedly, which makes the results hard 
to compare and generalize. Unstable patients in the acute phase with multiple organ failure 
are very different from patients tolerating full enteral nutrition, as those in the latter group are 
likely to be stabilized and less severely ill.  
The acute phase response and the prolonged catabolic phase of ICU long-stayers are 
homogenous parts of critical illness. Still, it is unlikely that there is a “magic bullet” treatment 
that is applicable for the entire ICU population (91). The knowledge gained from these trials 
and other studies has highlighted a number of conditions where glutamine might not be 
advisable in the ICU; acute liver failure associated with deranged metabolism, acute kidney 
failure not receiving dialysis (94), hemodynamically unstable patients in shock, and early 
phase unstable patients that do not tolerate nutrition.   
In conclusion, the effect of supraphysiological doses of glutamine has earlier only been 
described in cell cultures in vitro (9), it has not been explored in healthy subjects and seem to 
be unadvisable in critically ill. The possible role of glutamine to supplement a deficit in elect 
groups of critically ill patients is yet to be explored (64, 91, 95). 
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2 AIMS 
 
There is a considerable heterogeneity of existing studies over glutamine supplementation in 
critical illness. It comes in the results reported, in the patient cohorts investigated, and in 
doses and routes of administration. To explain the heterogeneity in results, a better 
understanding of glutamine kinetic in critically ill patients is necessary. Existing evidence do 
not exclude the possibility of beneficial effects from glutamine supplementation in some 
subpopulations of critically ill patients. Glutamine kinetics in critical illness is not sufficiently 
characterized to enable us to design the proper studies to sort out the hypothesis that low 
plasma glutamine represents a shortage of glutamine, which may motivate a supplementation. 
The overall aim of this thesis is to help to fill this gap of knowledge.  
 
The conventional method to study glutamine rate of appearance (endogenous glutamine 
production) with a constant infusion, is time-consuming. This constitutes a problem in the 
ICU setting, as there are frequent medical alterations that risks affecting the results when a 
measurement stretches over a longer time period. Hence, there is a need for an alternative 
method to study glutamine turnover in critically ill patients, in order to get a better 
understanding of the kinetics. One aim was, therefore, to establish and validate a bolus 
injection method for studying endogenous glutamine production, enabling shorter study 
periods (Study I).  
 
In clinical practice it will be plasma glutamine concentration that is available. However, it is 
unclear what it represents and how it relates to glutamine availability for tissues with high 
utilisation. If a low plasma glutamine concentration is caused by a low production rate, there 
is a rationale for glutamine supplementation. Therefore, a second aim was to investigate the 
relation between plasma glutamine concentration and endogenous production during critical 
illness (Study IV).  
 
A third aim of the thesis was to elucidate the relevance of plasma glutamine concentration to 
clinical conditions and outcomes in three observational studies. We explored this at discharge 
from the ICU and longitudinally in the post ICU period (Study II), in liver conditions (Study 
III) and when hyperglutaminemia was present at ICU admission (Study V). 
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3 STUDIES OVERVIEW 
 
3.1 STUDY DESIGNS AND EXPERIMENTAL PROTOCOLS 
I. A tracer bolus method for investigating glutamine kinetics in humans 
The study is comprised of 4 substudies.  
(1) Dose finding study: Bolus injections of [1-13C] glutamine were given to healthy 
volunteers (n=6) to find a dose that allowed accurate tracer determination in plasma with 
minimal effects on glutamine and insulin concentrations.  
(2) Variation study: Repeated measurements of endogenous rate of appearance (endoRa) 
were performed in four healthy volunteers (n=4) 3-12 days apart.  
(3) Alanyl-glutamine supplementation and parenteral feeding: Healthy volunteers (n=17) 
were given intravenous alanyl-glutamine supplementation (16.8 mg/kg/h glutamine, 
corresponding to a daily dose of 0.4 g/kg/24h) with and without parenteral nutrition, and the 
effect on the endoRa of glutamine was determined.  
(4) Alanine study: Since glutamine supplementation is given in the form alanyl-glutamine, 
healthy volunteers (n=7) were given intravenous alanine to determine whether it affects 
glutamine endoRa.  
 
II. Plasma glutamine concentration at ICU discharge: An observational study 
Fully fed ICU patients intravenously supplemented with glutamine for >3 days were studied 
at ICU discharge and post-ICU. Plasma glutamine concentration was followed on the day of 
discharge and every 5-7 day of the remaining hospital stay (n=63), and plasma glutamine 
concentrations 24-72 hours after discharge was related to 12 months all-cause mortality 
(n=100).  
 
III. Plasma glutamine concentrations in liver failure 
Four different groups of patients were studied; A) chronic liver failure (n = 40), B) acute on 
chronic liver failure (n = 20), C) acute fulminant liver failure (n = 20), and D) post-
hepatectomy liver failure (n = 20). Child-Pugh and Model for End-stage Liver Disease 
(MELD) scores were assessed as indices of liver function. Group A, chronic liver failure, was 
only sampled and evaluated once in the out-patient clinic. The three other groups were 
sampled and evaluated first on the day of ICU admission (groups B and C) or at the recovery 
room (group D), and thereafter every 3rd day (±1 day) during their hospital stay. Outcomes 
were recorded up to 48 months after study inclusion. 
 
IV. Endogenous production of glutamine and plasma glutamine concentration in 
critically ill patients 
The tracer bolus method developed in study I was applied to determine endoRa for glutamine 
in critically ill patients (n=20) with varying glutamine concentration at ICU admission, as 
screened by a point-of-care device.  
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V. Hyperglutaminemia at intensive care unit admission: An observational study 
Consecutive admissions to a mixed general ICU were included (n=269). A blood sample to 
be analysed for glutamine concentration was obtained within one hour from admission. 
Conventional risk scoring SOFA (Simplified Acute Physiology Score) and SAPS III 
(Sequential Organ Failure Assessment) at admission, and mortality outcomes for up to 12 
months were recorded for all included patients. 
 
3.2 SUBJECTS 
In study I, all 32 subjects were healthy volunteers recruited in accordance with the ethical 
review board application. 
Studies II, IV and V all include patients from the ICU of Karolinska University Hospital, 
Huddinge. The case mix includes both medical and surgical patients, where the surgical 
predominantly originate from transplant (liver and kidney) and major upper abdominal 
surgery (pancreas, ventricle, liver, and oesophagus). No traumatic injury, neuro or thoracic 
surgery patients are included. As the hospital is a liver transplant centre, patients with liver 
disease are overrepresented compared to other ICU populations in Sweden. 
Study II recruited ICU patients who had received glutamine supplementation in the ICU for 
>3 days before they were discharged from the unit. 
Study IV recruited patients in the ICU and study V included consecutive admissions to the 
ICU. 
Study III recruited patients to four groups from different clinics in the hospital. The patients 
with chronic liver failure were recruited at a planned appointment with their doctor at an out-
patient clinic. The two groups with acute or acute on chronic liver failure were recruited in 
the ICU. The post-operative patients were recruited in a high-dependency ward after surgery. 
 
3.3 ETHICAL CONSIDERATIONS 
Observational and kinetic studies can help us understand the mechanism behind hypo- and 
hyperglutaminemia and thereby elucidate which patients could be targeted for substitution, an 
intervention that could possibly save lives in a patient group with high mortality. This should 
be considered in relation to the potential discomfort, risk or harm associated with the studies. 
All study protocols were approved by the Regional Ethical Review Board, Stockholm, 
Sweden and conformed to the ethical guidelines of the Declaration of Helsinki. All patient 
and volunteer data were encrypted and kept safe.  
 
In study I, healthy volunteers received both arterial and venous catheters, associated with a 
minor discomfort. A total of 60 ml blood was collected, which is a negligible risk. A health 
questionnaire screening and health examination were performed by a trained physician, who 
also was available throughout the experimental protocol. Financial compensation was given 
to the subjects and they could withdraw from the study at any time. 
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In study II-IV, patients contributed with 9-30 mL of blood. The protocol was designed to 
minimize blood loss and this small volume is a negligible risk, also in the severely ill patients. 
The collection could be associated with a minor discomfort, when a separate venous puncture 
was necessary, but existing lines were used whenever possible. 
  
In study IV, the tracer injection is not harmful. With the original sampling protocol, however, 
we encountered a problem with failing arterial lines. This was considered an inacceptable 
complication for the patient as the arterial line is needed in the ICU to continuously monitor 
blood pressure and obtain arterial blood gases. We, therefore, made alterations in the protocol 
to only include stable patients where arterial line is not as crucial and, thereafter, to change 
the sampling protocol from 61 to 17 samples in order to protect the arterial lines. 
In study V, an extra vial of blood was collected along with routine samples at ICU admission. 
Informed consent to participate in the study was obtained retrospectively within one month, 
otherwise the sample was discarded.  
 
Informed consent is often not possible to obtain from critically ill patients due to altered 
mental status and sedation, a close relative is then asked on behalf of the patient. Another 
ethical issue with studying ICU patients is that, due to the severity of the illness, both patients 
and relatives often are in an emotionally vulnerable state when asked for participation in the 
study. However, as the metabolic changes and potential benefits are specific for this patient 
group there are no alternative candidates. 
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4 METHODS 
 
4.1 AMINO ACID ANALYSIS 
Glutamine tracer enrichment (amount of labelled glutamine in relation to total glutamine) is 
analysed by a gas chromatography-mass spectrometry (GC-MS) method described previously 
(96).  
We use two different methods to analyse glutamine concentration in the laboratory: 
1. Free glutamine concentration in plasma is analysed by GC-MS by adding [U-13C6] 
glutamine as an internal standard. This technique is used in parallel when enrichments are 
analysed (as above). 
2. Plasma glutamine concentration is analysed by high pressure liquid chromatography 
(HPLC) using an on-column derivatization with ortho-phtaldialdehyde/3-mercaptopropionic 
acid (OPA/3-MPA) and fluorescent detection as described earlier (97). This technique is used 
when glutamine concentration is needed without determination of enrichment. 
Plasma glutamine concentration is measured in the ICU employing a point-of-care device 
(Nova Biomedical’s BioProfile Analyser), where enzyme biosensors combine two 
membranes with enzymes and an electrochemical sensor to measure metabolites. Here 
accuracy is not on analytical level, but sufficient for clinical guidance and for characterization 
of patients for study inclusions (98). 
 
4.2 DISTRIBUTION AND BODY COMPARTMENTS 
A main purpose of this work is to assess the turnover of glutamine, to improve understanding 
and interpretations of plasma concentrations of glutamine. Turnover can be studied by using a 
labelled form of the metabolite, an isotopic tracer. 
The human body consists of a wide variety of tissue characteristics in terms of blood flow, 
water content, protein binding, and transport mechanisms over membranes related to size or 
electric charge of different metabolites. This will affect the distribution of different 
substances. For example, a lipophilic substance will accumulate in fat tissue and large 
molecules that do not move readily over capillary walls will stay in the plasma. 
To describe the data that is achieved through different experiments there is a need of 
simplifications of the human physiology. One such method is to mathematically divide the 
body into different compartments or metabolic pools (99). A metabolic pool has a 
hypothetical volume of distribution, seldom matching any physiological volume, with a 
homogenous concentration of the studied metabolite. Kinetic models rely on metabolic pools 
to describe the exchange of metabolites between them. The plasma metabolic pool is a central 
compartment, in exchange with most other compartments, and readily available for sampling. 
Other examples could be the intracellular milieu of a certain tissue like skeletal muscle cells 
or enterocytes.  
Glutamine is a small molecule that can easily move across cell membranes to be utilized by 
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tissues throughout the body. However, the intracellular concentrations are in general much 
higher than the plasma concentration (44, 61-63). Thus, the plasma concentration is just a 
small fraction of the total free glutamine pool, which has a large distribution volume, and it 
takes a very long time to reach equilibrium (6). Due to these characteristics, compartmental 
modelling for glutamine is complicated. Hence, we employ a non- compartment turnover 
model that due to the short measurement time mainly represents the flux of glutamine 
through plasma, the central compartment. 
 
 
 
Figure 3. Distribution of an injected substance in central compartment and subsequently in other 
compartments/tissues. 
 
4.3 TRACER METHODOLOGY TO ESTIMATE ENDOGENOUS PRODUCTION 
A tracer is an isotope labelled version of the substance of interest (tracee) and can be used to 
study its metabolism. A perfect tracer should biochemically behave and be metabolized in the 
same way as the tracee, but still be detectable as different from the tracee by some analytical 
method. We use stable isotope labelled [1-13C] glutamine and ring-2H5-phenylalanine, which 
both have a higher molecular mass than the most common natural form and can be measured 
separately by mass spectrometry. 
 
The concentration of a substance in plasma depends upon the rate of appearance (Ra) and the 
rate of disappearance (Rd), i.e. the flux into and out of plasma. In steady-state conditions, 
equilibrium prevails and Ra = Rd. The Ra is the sum of the production of the substrate 
(endogenous Ra) and the dietary intake of the substrate (exogenous Ra) that appears into 
plasma. Rd represents the substrate that leaves plasma and is comparable to clearance. 
To measure the Ra and Rd, the tracer can be introduced into the plasma pool either by a 
constant infusion or by a bolus injection (99). Most glutamine kinetic studies have used the 
constant infusion approach (100). During a constant infusion of the tracer, the concentration 
of the tracer in plasma will eventually reach a steady state. At that time, a single plasma 
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sample can give the ratio between the tracer and the tracee, and the percentage of the 
substance that is labelled can be calculated. This is called the enrichment and is often 
expressed as molar percent excess (MPE).  
𝑀𝑃𝐸 =
𝑇𝑇𝑅
𝑇𝑇𝑅 + 1
× 100% 
where TTR is the tracer/tracee ratio. 
To avoid that the tracer affects the tracee metabolism, the enrichment is kept as low as 
possible, while still allowing detection. This can be supported by the absence of significantly 
elevated plasma concentrations of the tracee and affected hormones. Because the Rd for tracer 
and tracee is equal, the ratio depends on the Ra, as it dilutes the tracer in the plasma pool (99).  
Because of the complex and uneven distribution of glutamine it can be difficult to achieve a 
steady state. Therefore, it is important that the subject has an overall stable metabolic 
situation during the study time. The constant infusion method for glutamine requires an 
infusion of at least 4-6 hours. ICU patients are dynamic and have frequent medical and 
nutritional alterations, which makes a shorter protocol more relevant and feasible. Therefore, 
a tracer bolus injection method was established and used in this project. 
A tracer bolus dose will give a quick peak in plasma followed by a decay curve of the 
enrichment. Again, Rd is assumed to be the same for tracer and tracee. Since the enrichment 
depends on the ratio, the slope of the decay curve depends upon the Ra that dilutes the tracer, 
as illustrated in Figure 4. 
 
Ra (µmol/kg/min) is calculated by the formula: 𝑅𝑎 =
𝐷𝑜𝑠𝑒
𝐴𝑈𝐶
   
where Dose is the amount of tracer injected in µmol per kg body weight and AUC is the Area 
Under the Curve of the MPE versus time plot.  
 
 
  
Figure 4. Decay plots after a tracer bolus dose. A) A high rate of appearance (Ra) will give a quicker dilution, a 
steep decay curve and a smaller area under the curve. B) A low Ra will give a slower dilution, a flatter decay 
and a larger area under the curve. 
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The glutamine entering plasma can derive from exogenous supply or endogenous release 
from cells. Enteral supply affects plasma concentrations only to a small extent due to 
splanchnic extraction and was therefore disregarded in study IV (14, 15). If the patient had 
parenteral supply, this was subtracted in the calculations. 
 
The endogenous Ra (endoRa) of glutamine in plasma can originate either from de novo 
synthesis or protein break down in cells. To differentiate them, we use a phenylalanine tracer 
together with the glutamine tracer to estimate protein breakdown. The Ra of phenylalanine is 
calculated in the same way as for glutamine. However, as it is an essential amino acid that 
cannot be synthesized by humans, the Ra is assumed to come from protein breakdown only. 
By estimating the fraction of phenylalanine compared to glutamine from protein breakdown it 
is then possible to calculate glutamine Ra from protein breakdown and de novo synthesis 
respectively. A whole-body protein content of 7% glutamine and 4,2% phenylalanine was 
assumed for this calculation (101). 
 
Clearance is the volume of plasma from which the substance is completely removed per unit 
time (L/min). Glutamine clearance was calculated by the formula:  
 
 𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 =  
(endoRa × body weight)
plasma concentration
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4.4 BOLUS INJECTION METHOD 
Subjects received an intravenous bolus injection of both glutamine and phenylalanine labelled 
with a stable isotope (1-13C-glutamine 3 mg/kg and ring-2H5-phenylalanine 0.3 mg/kg). A 
baseline sample was obtained prior to the bolus, next the bolus was given over 20 seconds, 
followed by 60 blood samples over 90 min to get a decay curve. A catheter in the radial artery 
is used for blood sampling, every 30 sec up to 10 min, then every minute up to 30 min and 
finally every 3 min up to 90 min (figure 5). Each blood sample is 0.5 mL resulting in a total 
sampling volume of 30 ml of blood. 
  
Figure 5. An illustration of the sampling protocol. 
 
Measurements stop at 90 minutes. However, the decay curve is not completely back to 
baseline at that time (figure 6). The final slope of the curve levels out and, therefore, the AUC 
after 90 minutes was extrapolated from the slope of the last measurements that appear to be 
on a straight line in the log domain of the curve (lambda z). 
  
Figure 6. Illustration of the extrapolation of the decay curve after 90 minutes.  
 
When the method was developed, this rather extensive sampling protocol was deemed 
necessary. Fewer initial samples could give significant differences from the default sampling 
protocol as the initial peak is not captured accurately, which tends to underestimate AUC, 
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resulting in a higher rate of appearance. Moreover, a shorter time period would have a 
significant effect on the calculated rate of appearance, as the extrapolation of the tail of the 
curve down to baseline becomes inaccurate as the curve has not levelled out enough yet. In 
summary, to achieve best accuracy both peak and tail needed to be well characterized. 
  
4.4.1 Simplified sampling protocol  
In study IV, a need for a simplified protocol was detected, as the frequent sampling 
jeopardized the arterial lines of the ICU patients. Hence, the protocol was substantially 
downsized from 61 to 17 samples. In the new protocol, a baseline sample was collected 
before the bolus injection, and after the bolus injection of tracer, blood was collected at 0.5, 1, 
2, 4, 8, 12, 16, 20, 25, 30, 39, 51, 60, 69, 81 and 90 min. 
 
   
Figure 7. An illustration of the simplified sampling protocol. 
    
Before this alteration, calculations were made to ensure that the tracer kinetics could be 
defined with a similar accuracy from fewer samples. To capture the peak correctly, there is 
still more abundant sampling right after the bolus injection, then sparser towards the end, but 
the 90 minutes protocol is intact. 
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Figure 8. Calculations to validate a reduction of the number of samples needed to determine a correct AUC and 
ensuring that the tracer kinetics could be defined with a similar accuracy from fewer samples. The endoRa for 
both glutamine (Gln) and phenylalanine (Phe) were calculated with both 61 and 17 samples, using data from the 
first eleven patients of study IV.  
 
To overcome the problem with overestimation of the AUC the linear-up log-down 
trapezoidal method was used instead of a linear only trapezoidal model.  
When the AUC is calculated using the trapezoidal model, the difference between each time 
point makes up one piece, looking like this: 
    
Then all the pieces are added together to give the total AUC. However, the actual slope is 
curved and when the line between the timepoints is straightened, it results in a too large 
AUC. Fewer time points make these lines longer and enhances this effect, which results in a 
larger overestimation of AUC. If the calculation is done in the log domain instead (linear-up 
log-down trapezoidal method), the result is a slightly curved line, which gives more accurate 
results. 
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4.5 STATISTICAL METHODS  
 
In table 2, an overview of the statistical methods used is presented. For normally distributed 
continuous data Student’s t-test was used, whereas Mann-Whitney u-test or Wilcoxon signed 
rank test was used when values were not normally distributed, according to Shapiro Wilk’s 
normality test. Categorical data was analysed with Fisher´s exact test. 
In study I, substudies 1 and 3, were analysed with a paired t-test, as volunteers acted as their 
own controls. In substudy 2, the effect of alanyl-glutamine and parenteral feeding was 
analysed using analysis of variance (ANOVA), followed by Dunnett’s post-hoc test.  
In study II and V variables showing statistical significance (p <0.05) in univariate analysis 
were included in a forward stepwise multivariate regression or a multiple logistic regression 
to exclude confounders. 
Spearman’s rank correlation was used to compare plasma glutamine concentrations with liver 
function measured as MELD and Child-Pugh score (study III), clearance (study IV) and 
variable parameters (study V), whereas linear regression was used to compare plasma 
concentrations to rate of appearance (study IV). 
In study III, high plasma glutamine values (cut-off 930 µmol/L) were related to Child-Pugh 
and MELD scores by receiver operator characteristics (ROC) curves. 
In study V, Kaplan Meier and log rank test was used for survival analysis and comparison 
between the groups. Also, a ROC curve analysis of six-months mortality and plasma 
glutamine concentration was performed to identify a cut-off for predicting mortality. 
 Descriptive statistics Statistical tests 
Study I Mean, standard deviation Paired t-test 
Analysis of variance (ANOVA), 
Dunnett’s post-hoc test 
Study II Median, interquartile 
range 
Mann-Whitney U-test, Wilcoxon 
signed rank test, 
Fisher’s exact test, 
Univariate logistic regression,  
Stepwise forward multiple 
logistic regression 
Study III Median, range Spearman’s rank correlation, 
Receiver operating characteristic 
(ROC) curves  
Study IV Mean, standard deviation 
Median, range 
Student’s t-test,  
Mann-Whitney U-test, 
Linear regression, 
Spearman’s rank correlation 
Study V Mean, standard deviation 
Median, interquartile 
range 
Student´s t-test,  
Mann-Whitney U-test,  
Fisher’s exact test, 
Pearson’s correlation,  
Spearman’s rank correlation, 
Kaplan Meier survival analysis,  
Log rank test, 
Univariate logistic regression, 
Multiple logistic regression 
ROC curve 
Table 2. Overview of statistical methods.  
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5 MAIN RESULTS AND DISCUSSION 
 
5.1 STUDY I AND IV 
A tracer dose of 3 mg/kg 13C-glutamine was chosen for the bolus injection method, as that 
gave a reliable decay curve and only resulted in a short peak in plasma glutamine 
concentration from 500 µmol/L to 1200 µmol/L over the first two minutes. Insulin 
concentration was unaffected. 
To confirm reproducibility, four subjects were measured on two occasions. The coefficient of 
variation between two measurements was 5.5%, whereas the GC-MS analytical coefficient of 
variation was found to be 4.1%. Hence, the variation in rate of appearance was mostly due to 
the analytical variation. 
Intravenous alanyl-glutamine supplementation increased plasma glutamine concentrations. 
Parenteral nutrition together with alanyl-glutamine gave an increase in glutamine endoRa, 
whereas alanyl-glutamine supplementation only did not. Thus, the increased plasma 
glutamine concentration did not have a negative feedback mechanism on the glutamine 
endoRa, indicating that glutamine production is not directly affected by the plasma 
concentration. 
As an alanyl-glutamine dipeptide is used for glutamine supplementation, the effect of a pure 
alanine infusion was studied. Alanine did not have any detectable effect on glutamine endoRa 
and is therefore probably not a significant stimulus for glutamine synthesis. 
 
The bolus injection method is more convenient in an ICU patient group as the study protocol 
is only 90 minutes, which increases the chance that the patient is metabolically stable during 
the measurement period, compared to the constant infusion method that needs 4-6 hours of 
metabolic stability. For the study to interfere as little as possible with the general care of the 
ICU patients, it is also important that the method is valid during parenteral nutrition and 
glutamine supplementation. 
The endoRa measured by the bolus method in postabsorptive, healthy volunteers (study I) 
ranged between 4.5-7.5 µmol/kg/min, mean 5.7 ±0.7, which is comparable to previous 
reports from constant infusion studies, as depicted in Figure 9A (102, 103).  
In study IV, glutamine endoRa was measured in nineteen critically ill patients. Eight patients 
had a hypoglutaminemia (<400 µmol/L) and eleven patients had plasma glutamine 
concentration within the reference range  (400-930 µmol/L), mean concentration was 468 
(range 199-830) µmol/L. Glutamine endoRa was 8.9 ± 2.8 µmol/kg/min, of which 7.0 ± 2.7 
µmol/kg/min was de novo synthesis. There was a significant correlation between plasma 
concentration and both glutamine endoRa and de novo synthesis, R
2 0.35 for both.  
 
The endoRa in the ICU patients included in this study corresponds to 1.9 g of 
glutamine/kg/day (1.5 g/kg/day de novo production), which is high compared to previous 
reports, see figures 9B and 9C. ICU patients fasted for 10-24 hours are reported to have  
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glutamine endoRa between 4.9 ± 0.3 and 5.7 ± 0.3 µmol/kg/min (1.0-1.2 g/kg/day) (33, 42, 
104). A major difference is that most included patients in our study were in the fed state, 
whereas most previous studies on glutamine rate of appearance are performed on 
postabsorptive patients. However, the effect of nutrition on glutamine endoRa in ICU patients 
has been scarcely studied, and the few studies done give conflicting results. Addition of 
parenteral nutrition has been reported to have no effect on glutamine endoRa compared to the 
postabsorptive state (33). Likewise, a report on the effect of enteral nutrition on glutamine 
rate of appearance in healthy volunteers given high dose cortisol, showed no difference 
compared to fasted state, and a decrease in glutamine endoRa when extra glutamine was 
added to the nutrition (105). As cortisol stimulates glutamine synthesis, it is, however, 
possible that glutamine synthesis rates were already enhanced in these healthy subjects, 
before nutrition was provided (48, 49). In contrast, the results from study I show that 
parenteral nutrition increases rate of appearance in healthy subjects. Similarly, both parenteral 
and enteral nutrition have been reported to increase glutamine endoRa in healthy volunteers 
(106, 107). We hypothesize that a continuous provision of other amino acids results in a 
higher substrate availability for glutamine synthesis. 
 
Another difference in our protocol is the use of 13C glutamine tracer, where most other 
studies used 15N glutamine, either on the amino group (2-15N) or on the amide group (5-15N). 
The carbon skeleton is more stable than the amino and amide groups that can both be easily 
lost by transamination. The 13C tracer has been reported to show a 15-22% higher endoRa 
than the 15N tracer (n=8) (6, 103). Possibly, this is the result of a recycling of the nitrogen 
label that may then re-enter the plasma pool attached to a new glutamine molecule (103). 
This would, in turn, result in a slower dilution of the tracer and thereby a lower rate of 
appearance. The amide group is hydrolysed in the first step and is therefore more likely to be 
recycled. Accordingly, the 5-15N tracer gives a lower endoRa than the 2-
15N tracer (100). 
  
The shorter study time in our protocol also affects the results in a way that will give a higher 
endoRa. Glutamine is a small molecule that moves back and forth over cell membranes. 
When the infusion is given over a long time, a considerable amount of the tracer will have 
entered the intracellular space, which increases the likelihood that a labelled glutamine 
molecule re-enters plasma. This will blur the picture and give a lower endoRa, together with 
15N recycling making “new” glutamine molecules look like tracers that will therefore not be 
detected. Also, the tracer distribution to other pools increases over time and thus, the endoRa 
will more and more represent the whole-body glutamine flux, which is lower than the 
exchange in the plasma pool. This is demonstrated when the infusion time is stretched to 
eleven hours, resulting in a lower endoRa (6). In comparison, our shorter protocol will be less 
affected by label recycling and can therefore be argued to be a truer reflection of the 
glutamine flux into plasma. 
  
Other possible explanations for our higher glutamine endoRa are the inclusion of patients 
with a higher plasma glutamine concentration (mean 427 and 454 µmol/L) compared to other 
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measurements in ICU patients (mean 237, 340 and 357 µmol/L) (33, 42, 104), which 
according to our results would result in a higher rate of appearance. Moreover, the patient 
cohorts differ and may not be comparable. Two of the endoRa reports are based on 
postoperative patients in the acute phase after emergency abdominal surgery (33, 104), which 
are likely metabolically different from our stabilised patients with mostly respiratory failure. 
The metabolic status and level of inflammation and stress are likely to affect results. Burn 
patients fasted for eight hours had a glutamine endoRa of 7.2 ± 1.5 µmol/kg/min (108). These 
patients constitute a special cohort with high metabolism, but they were also studied during a 
stabilised phase. 
Regardless whether the glutamine endoRa in study IV is overestimated or more correct 
compared to others, the assumptions made can be assumed to be equal for all patients and 
thus, the correlation to plasma concentration is still valid. 
 
In addition, most previous studies use a leucine tracer instead of phenylalanine to estimate 
whole body protein break down. These two tracers have been reported to give similar values 
when used in parallel (6). However, in studies on healthy volunteers using phenylalanine the 
estimated protein break down is 15-21% of total endoRa (102) as opposed to 30-50% when 
leucine is used (104, 106). In our studies, the estimated proportion of glutamine deriving from 
protein break down is 15-18%, whereas others, using leucine, report this proportion to be 30-
45% (33, 104) in ICU patients. Hence, it is possible that this difference is partly explained by 
the use of different amino acid tracers. 
Due to these differences, the results of study IV are most closely comparable to the previous 
report from our working group, applying the same method on fully fed ICU patients, with 
similar glutamine endoRa (76). 
  
Because of the non-steady state in other pools, the endoRa probably primarily represents the 
transport of nitrogen between tissues through the plasma pool, the glutamine-glutamate cycle, 
rather than the intracellular production (100). Glutamate is the substrate for GS and glutamate 
plasma concentration has been reported to positively correlate with the efflux of glutamine 
from skeletal muscle (26). In burn patients it has been reported that glutamine production and 
utilization within the muscle cells are both increased to a similar extent and that the glutamine 
that appears in plasma originates from an increased net export of free glutamine in muscle 
that is maintained despite the lower intracellular concentration (25). A complete equilibration 
with an isotopic steady state between different glutamine pools will not be possible, therefore 
an estimate of the flux through plasma may be the best possible reflection of glutamine 
production. However, as our aim is to have a better understanding of plasma concentrations, 
the flux into plasma is the relevant measure, not intracellular production that never enters 
plasma. 
 
A limitation when studying the altered glutamine kinetics in the critically ill, is that the 
patients have a low plasma glutamine already at arrival. The profound muscle depletion is 
also present already at ICU admission, or soon after admission. These conditions are then 
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maintained throughout the ICU period; the patients with low admission plasma glutamine in 
general continue to stay low, and the intracellular muscle glutamine remains depleted. A new 
steady state of altered glutamine balance is created, that is quite different from that of a 
healthy person, especially considering concentration gradient across cell membranes. The 
conditions of this new steady state can be studied, but the transition between the two states is 
not accessible in clinical practice. Giving endotoxin to healthy volunteers is a possible way to 
simulate the alterations seen in early sepsis, however these changes will likely be less 
dramatic than the full scale acute response of life-threatening critical illness (97). 
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 Figure 9. Overview of endoRa and de novo synthesis of glutamine from previous reports. 
* 2-15N tracer  ¤ 5-15N tracer  
A) Healthy volunteers, study I bolus method compared to previous constant infusion studies (42, 100, 102-106, 
108, 109). B) Non-critically ill patients with abdominal diseases (6, 109-111). C) Critically ill patients, study IV 
compared to previous reports (33, 42, 76, 104, 108). 
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5.2 STUDY II, III AND V 
Study II was designed after The Scandinavian Glutamine Trial, showing a reduced ICU 
mortality in the glutamine supplemented group, which was abolished six months after ICU 
discharge (78). Two questions appeared; (i) did the patients develop hypoglutaminemia when 
supplementation was discontinued, and (ii) would plasma glutamine concentrations post ICU, 
in a non-supplemented state, be predictive for six months mortality? A patient cohort similar 
to the treatment group was therefore studied, and the results were that (i) ICU survivors had 
normal plasma glutamine concentrations post-ICU, without supplementation, and (ii) the 
post-ICU plasma glutamine concentration was not a mortality predictor. 
When supplementation was discontinued, plasma glutamine concentrations decreased, but 
remained within the reference range. Out of the 210 post-ICU samples collected, 89% were 
within the reference range for plasma glutamine concentration; only six were <400 μmol/L 
and sixteen >930 μmol/L. A majority (63%) of the high values where measured during 
readmission to the ICU, with glutamine supplementation reinstated. 
In a post hoc analysis of the samples collected on the day of discharge, during ongoing 
supplementation, twelve-months survivors (n=40) had lower plasma glutamine 
concentrations, and lower discharge SOFA scores than non-survivors (n=23). A stepwise 
multiple regression analysis indicated that discharge plasma glutamine concentration added to 
the mortality predictive power of discharge SOFA score. A higher concentration during 
supplementation, still within the reference range, appeared to be a sign of unfavourable 
prognosis. However, the interpretation of this post hoc finding should be done with caution. 
Especially as the same patients after discontinuation of supplementation no longer had a 
plasma glutamine concentration associated with an increase in mortality. 
  
Previous reports suggest that around one third of unselected patients admitted to a general 
ICU are hypoglutaminemic at admission and that this is associated with a higher mortality 
(36, 53). In the report from our working group, hyperglutaminemia was also associated with a 
higher mortality (36). In parallel, the results from the REDOX trial associate a high dose 
glutamine supplementation to a higher mortality (72). A third argument to investigate 
hyperglutaminemia is the well-known, but unclearly defined, association between high 
plasma glutamine concentrations and liver conditions (73). As earlier publications were 
indistinct to the type of liver condition, our first step was to design a study to explore plasma 
glutamine status in four different groups of liver insufficiency (study III). Thereafter, we 
launched a new study on ICU admission plasma glutamine concentrations including a more 
extensive clinical characterisation as compared to earlier studies (study V). 
 
Four groups of patients with liver insufficiencies were studied. Patients with chronic liver 
failure (group A, n=40) were sampled once at a routine visit to a hepatology outpatient clinic. 
In this group 78% had plasma glutamine concentrations within the reference range, and 20% 
had hyperglutaminemia (>930 μmol/L). After twelve months, mortality was 48% and another 
20% were liver transplanted. 
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Patients with acute-on-chronic liver failure (group B, n=20) and patients with acute fulminant 
liver failure (group C, n=20) were followed every third day from ICU admission. At 
admission 60-65% were hyperglutaminemic. After twelve months, patients in group B had a 
mortality of 85% and the remaining 15% were liver transplanted. Patients in group C had the 
lowest twelve-months mortality (15%), although 25% were liver transplanted.  
Patients subjected to major hepatectomy (50-90% of the liver removed) were recruited in a 
high-dependency ward the day after surgery (group D, n=20). In this group 70% had plasma 
glutamine concentrations within the reference range and 20% had hyperglutaminemia. 
Among the hyperglutaminemic cases at inclusion (n=4), two died during the acute 
postoperative phase and two were still alive after twelve months. 
 
To grade liver insufficiency, Child-Pugh and MELD scores were used. These scoring systems 
were developed to estimate prognosis in chronic liver failure and could therefore be assumed 
to indicate a more advanced liver disease (112, 113). Although not validated for acute liver 
failure or post hepatectomy liver failure, they are widely accepted as a reflection of the 
severity of liver insufficiency, and they were therefore used in all patient groups to enable 
comparison. When all four groups were combined (n =100) there was a positive correlation 
between plasma glutamine concentration and the degree of liver failure, reflected as Child-
Pugh and MELD score. The four groups of subjects with liver conditions recruited in study 
III are case series, which makes comparisons between the groups and subjects in other studies 
difficult. The main result of the study was the identification of acute-on-chronic and acute 
fulminant liver insufficiency as the conditions most frequently associated with 
hyperglutaminemia, and the perspective that the survival prognosis in these groups was quite 
different. 
 
In study V, plasma glutamine concentration was measured within one hour from admission in 
consecutive ICU admissions (n= 269). Admission hyperglutaminemia ≥930 µmol/L (n=26) 
was associated with a higher six months mortality compared to admission plasma glutamine 
<930 µmol/L (n=243); 46% versus 18%. In the group of patients with hyperglutaminemia, 
85% had liver disease and/or signs of acute liver damage at ICU admission and the two major 
admission diagnoses were postoperative liver transplant and acute liver failure. 
 
When the study protocol was designed, postoperative care of liver transplantation patients 
recruited from the waiting list were not identified as a subgroup that needed special attention. 
However, when the results were analysed it was obvious that a post hoc separation of these 
patients was motivated, as they had no six-months mortality, the admission criterion was 
relative, and the median ICU stay was less than 24 hours. Out of the 26 patients with 
hyperglutaminemia, seven were admitted postoperatively after liver transplantation, and if 
they were excluded six months mortality was 63% in the hyperglutaminemic group.  
When multiple regression was applied to predict six months mortality in all subjects (n=269), 
hyperglutaminemia, admission SOFA score and age were independent predictors. This 
finding became stronger when the postoperative liver transplantation patients were excluded 
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(n=226). Also, the previous finding of a cut-off for predicting six-months mortality of 930 
µmol/L was confirmed with a receiver operating characteristic curve, which strengthens 
hyperglutaminemia as a predictor of poor outcome (36). A unique feature of this study 
compared to other available studies on plasma glutamine concentrations at admission, is that 
all samples were collected within an hour after ICU admission, instead of within 24 hours, 
and that there are no missing values in the included patients. 
 
Study V is a report over a secondary aim of a study protocol that focused both on hypo- and 
hyperglutaminemia. However, the present patient cohort only contained 15% (40/269) 
hypoglutaminemic patients and there was no increased mortality in this group. As a result, the 
findings of the previous study from our working group was not reproduced (36). The most 
likely reason for this is that the exclusion criteria differed, which unintentionally resulted in a 
different case mix. In the present study several patients were excluded due to a do not 
resuscitate order at admission or because of an early death before informed consent could be 
obtained. The exclusion of these two groups constitutes the main difference between the 
cohorts included in the two studies. Although unknown, it is possible that these excluded 
patients had a high prevalence of hypoglutaminemic patients. This finding emphasises the 
problem to compare studies in the ICU with different inclusion criteria, which may result in 
completely different cohorts in this very heterogenous patient group, even when included in 
the same ICU. 
 
The results of study III and V emphasises the role of the liver in glutamine metabolism. The 
positive correlation between hyperglutaminemia and bilirubin, ALT and AST in study V is 
consistent with previous reports (31, 57) and highlights the connection between liver disease 
and high plasma glutamine concentrations. Although liver failure has repeatedly been 
reported in connection with hyperglutaminemia before (31, 36, 57, 73), this is now clearer 
described by the link to acute liver decompensation and the finding that a more advanced 
liver disease is more likely associated with hyperglutaminemia. 
  
The mechanism that connects a high plasma glutamine concentration to a higher mortality is 
unknown. However, the present results do not support that a high glutamine concentration per 
se is toxic. Rather, it is a biomarker that indicates a severe metabolic malfunction that is a 
highly unfavourable prognostic sign, if present at ICU admission together with organ failures. 
The connection between liver decompensation and hyperglutaminemia supports this theory. 
The finding that hyperglutaminemia had no connection to mortality in the patients that had 
already had a liver transplantation also suggests that the glutamine concentrations per se are 
not a problem, but rather the metabolic capacity, which has been restored in these patients. 
The patients in study III show a similar pattern (figure 10). The same trend can be seen in a 
report of plasma glutamine concentrations over time in select ICU long-stayers. The mortality 
of patients with a plasma glutamine concentration >830 µmol/L in a second sample was 
100%. Likewise, the survivors among the hyperglutaminemic patients exhibited a dramatic 
decrease in plasma glutamine concentration. Also, 25% of non-survivors show a sudden, 
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dramatic increase to hyperglutaminemic levels, without the influence of glutamine 
supplementation (31). This trend can, to some extent, also be seen in the temporal pattern of 
post ICU plasma glutamine concentrations (study II), where the outliers that showed dramatic 
increases and pronounced instability in plasma concentrations died shortly afterwards 
Hence, it is possible that hyperglutaminemia is a biomarker associated with a failing energy 
metabolism, incapable of keeping up intra/extracellular concentration gradients at the end of 
life. Still, it is reversible, and the patient outcome seems to be highly dependent on the ability 
so normalise plasma glutamine concentration, or the restoration of metabolic balance, that 
this possibly indicates. Thus, the specificity of hyperglutaminemia as a biomarker for 
unfavourable outcomes is lower than the sensitivity at ICU admission, particularly in the case 
of a single organ failure. 
  
Figure 10. Plasma glutamine concentrations over time (measured 3 days apart) in patients with acute fulminant 
or acute-on-chronic liver failure from ICU admission, study III divided into A) acute phase non-survivors (died 
within one week after the last sample) and B) survivors. Light blue area indicates the reference range (400-930 
µmol/L). Black lines indicate patients with at least one value >930 µmol/L. 
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
The main conclusions are: 
• A tracer bolus injection method was validated to measure glutamine endogenous 
production in humans with good reproducibility and small variation (study I).  
 
• There was a positive correlation between plasma glutamine concentration and 
endogenous glutamine production in critically ill patients, where 35% of the 
variability in endogenous production could be attributed to variability in plasma 
glutamine concentration, or the other way around (study IV). 
 
• In the post ICU period without exogenous glutamine supplementation, plasma 
glutamine concentrations were within the reference range and were not related to 
mortality (study II). 
 
• In liver failure, regardless of aetiology, severity and course of illness, a high plasma 
glutamine concentration was a common finding, although most frequent in patients 
with acute fulminant and acute-on-chronic liver failure. There was a positive 
correlation between the severity of liver failure and plasma glutamine concentration 
(study III).  
 
• Hyperglutaminemia (≥930 µmol/L) at ICU admission was an independent predictor 
for high mortality. A majority of these patients had a liver condition, although 
hyperglutaminemia was also observed in patients without signs of liver affection 
(study V). 
 
The role of glutamine in critical illness is still not settled. The finding that low plasma 
concentrations correlates with a lower endogenous production keeps the possibility open that 
there is a cohort of critically ill patients with too low glutamine availability who would 
benefit from exogenous glutamine supplementation (114). In addition, there is only one study 
on exogenous glutamine supplementation in critical illness that demonstrate harm (72). It is 
dissatisfying that the mechanism behind that harm has not been explored and explained. Our 
observations give no indication of toxic effects of glutamine, per se. Hyperglutaminemia was 
potentially reversible even in cases with very high plasma concentrations. Hence, glutamine 
kinetics in critical illness needs to be further clarified.  
 
The simplified version of the tracer bolus injection method makes it possible to gain more 
information of glutamine endoRa in the ICU setting. In critically ill patients with glutamine 
plasma concentration in the low or normal range there is a relation to endoRa. Still, the 
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pathophysiology of hyperglutaminemia is so far poorly understood and needs to be studied 
further. Especially in the context of liver failure, is it to be regarded as a biomarker or as a 
causative factor to symptomatology? To study glutamine endoRa in hyperglutaminemic 
patients with and without liver failure would therefore be helpful.  
 
The non-compartmental model employed in the tracer bolus method does not allow 
measurements of the total endogenous glutamine production. It reflects the influx into the 
central plasma compartment. With repeated measurements over time, it can give information 
of the endogenous glutamine production over the course of critical illness. The short-term 
measure of glutamine flux trough plasma is probably the best estimate available for 
endogenous glutamine production in this context, and the most relevant for plasma 
concentrations of glutamine.  
 
The effort to empirically link hyperglutaminemia, liver conditions, and mortality emphasizes 
the complexity of these relations. Hyperglutaminemia is more common in liver conditions, 
increasingly so with more severe liver disease and especially in combination with critical 
illness. Still, liver failure is not always accompanied by hyperglutaminemia, and the condition 
also exists in patients without signs of compromised liver function. The mortality risk in these 
patients is high, but the prediction is not absolute. As these patients are not common, our 
cohort was not big enough for this aspect of the study, but it served as hypothesis generating. 
Future observational studies should screen for hyperglutaminemia at admission and 
longitudinally follow plasma concentration and endoRa. A sustained high or unstable high 
plasma glutamine concentration may be associated with unfavourable outcomes, this is a 
hypothesis generating observation from our case series in studies II and III, that could be 
further explored. 
 
A conclusion of this thesis is that hyperglutaminemia at ICU admission is associated with a 
higher mortality risk. This is not a new finding, but it emphasizes that plasma glutamine 
concentration is of importance for the critically ill, and as such deserves attention. Future 
studies with analyses of plasma glutamine concentration daily to follow the course 
longitudinally combined with measurements of glutamine endoRa will contribute to a better 
understanding. The ultimate question if plasma glutamine concentration is just a biomarker or 
if it also gives signal of a deficit and/or an impaired handling of glutamine is still pending. 
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Kritisk sjukdom innebär en livshotande svikt i ett eller flera vitala organ, vilket medför en 
extrem stress där kroppen pressas till det yttersta för att försöka överleva. Det leder i sin tur 
till flera kroppsliga förändringar som är unika för detta tillstånd. Intensivvård kan stötta 
sviktande organsystem och hålla patienten vid liv medan kroppen får en chans att återhämta 
sig. 
 
Syftet med denna avhandling är att kartlägga delar av omsättningen av glutamin hos kritiskt 
sjuka patienter. Glutamin är en aminosyra, de beståndsdelar som bildar proteiner. Det är den 
vanligast förekommande aminosyran i kroppen och varje dag produceras 65-85 gram, 
framförallt i muskelceller. Glutamin har flera viktiga funktioner i kroppen utöver att bygga 
proteiner. Det är den primära energikällan för vita blodkroppar och tarmceller. Den används 
för att bygga DNA, RNA, glukos och viktiga antioxidanter. Glutamin påverkar även 
processer för cellöverlevnad och celldelning, samt används för att transportera 
kväve/ammoniak mellan vävnader och för att producera bikarbonat för att reglera pH-
balansen.  
 
Studier har visat att både för hög och för låg glutaminkoncentration i plasma vid inskrivning 
till intensivvårdsavdelningen (IVA) är kopplat till en ökad dödlighet. Man vet också att 
muskelceller, som normalt innehåller mycket höga halter av glutamin, tömmer 70-80% av sin 
fria glutamindepå under den akuta fasen av kritisk sjukdom. Därefter fortsätter en omfattande 
nedbrytning av skelettmuskulaturen och dess proteiner. En av orsakerna tros vara att 
upprätthålla en hög utsöndring av glutamin till resten av kroppen. Kombinationen av att 
kroppens glutaminförråd i muskler utarmas och att patienter med låg plasma-
glutaminkoncentration har en ökad dödlighet, har gett upphov till teorin att kritisk sjukdom 
kan leda till glutaminbrist. Omkring 30% av IVA-patienterna har låg plasma-
glutaminkoncentration och hypotesen är att de kan gynnas av extra glutamintillförsel. Ett 
flertal studier har genomförts men de skiljer sig stort i vilka patienter som har inkluderats, 
vilken dos glutamin som har getts, om de tillförts intravenöst eller via tarmen, samt när och 
hur länge man givit glutamin. Resultaten är därmed spretiga och svåra att jämföra. Flera 
studier har visat att glutamintillförsel leder till minskad dödlighet, kortare sjukhusvistelse, 
snabbare sårläkning och färre infektioner. Men en stor, randomiserad, klinisk studie där man 
gav väldigt hög dos glutamin (dubbelt jämfört med tidigare studier) till de allra sjukaste 
patienterna på IVA, i det akuta förloppet, visade istället på ökad dödlighet i gruppen som fick 
glutamin. Innan dessa resultat publicerades sågs glutamin som något helt ofarligt som kunde 
gynna vissa patienter och det ansågs därför rimligt att ge det till alla. Nu är ståndpunkten 
istället att om det kan vara skadligt för några så ska det inte ges till någon.  
 
Tyvärr har ingen randomiserad studie på glutamintillförsel mätt plasma-
glutaminkoncentration och selekterat patienter med låg koncentration. Därför har den 
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ursprungliga teorin, att det är dessa patienter som skulle gynnas, aldrig testats.  
För att få klarhet i om glutamintillförsel kan gynna somliga IVA-patienter behövs en större 
förståelse för vad som orsakar de avvikande glutaminkoncentrationerna. Dels för att förstå 
om en låg koncentration utgör en brist som behöver ersättas med extra tillskott, men även 
vilka patienter som utvecklar höga glutaminkoncentrationer och om detta i sig ger en ökad 
dödlighet.  
 
Avhandlingen består av fem delarbeten. 
Studie I och IV: För dessa studier används en isotopmärkt version av glutamin med en 
kolatom utbytt till 13C istället för 12C, vilket gör molekylen något tyngre och den kan då 
särskiljas i analys. Man mäter sedan hur proportionen av vanligt glutamin och 13C-glutamin i 
plasma förändras över tid. Eftersom de försvinner ur plasma i samma takt så beror den 
minskade proportionen av isotopmärkt glutamin på hur mycket kroppseget glutamin som 
kontinuerligt flödar in i plasma och späder ut det märkta. Man kan därigenom mäta hur 
mycket glutamin som produceras. Den tillgängliga metoden med kontinuerlig intravenös 
tillförsel av 13C-glutamin är ett tidskrävande protokoll som kräver att patienten är stabil och 
tillgänglig för studien under 4-6 timmar. Detta är svårt att uppnå hos kritiskt sjuka patienter, 
så i studie I utvecklades en ny metod för att studera omsättningen av glutamin. Istället för en 
kontinuerlig tillförsel över lång tid så gavs en hög stötdos (bolusdos) med 13C-glutamin och 
sedan tas upprepade blodprover för att mäta hur snabbt proportionen av 13C-glutamin avtar 
under 90 minuter.  
Studie I består av fyra delstudier med friska försökspersoner:  
1. Lämplig bolusdos bestämdes. 
2. Reproducerbarhet kontrollerades, det vill säga att upprepade mätningar hos samma person 
gav likvärdiga resultat. 
3. Effekten av intravenös näring- och glutamintillförsel kontrollerades. Att tillföra glutamin 
ökade plasmakoncentrationen, men påverkade inte den kroppsegna produktionen. Tillförsel 
av både glutamin och intravenös näringslösning ökade glutaminproduktionen, vilket antas 
bero på den ökade tillgängligheten av andra aminosyror som omvandlas till glutamin. 
4. Intravenöst glutamin ges som en dipeptid; aminosyran alanin ihopkopplad med glutamin. 
Om alanin direkt omvandlas till glutamin skulle den ökade glutaminproduktionen bero på 
alanin-tillförseln. Detta skulle kunna maskera en eventuell negativ feedback-mekanism från 
det tillförda glutaminet. För att kontrollera detta tillfördes enbart alanin, vilket inte hade 
någon påverkan på glutaminproduktionen.  
 
För att få en ökad förståelse av den förändrade omsättningen av glutamin vid kritisk sjukdom 
och klargöra varför vissa patienter får låg plasmakoncentration användes bolusmetoden för att 
mäta kroppsegen glutaminproduktion hos intensivvårdspatienter (studie IV). Produktionen 
jämfördes sedan mot plasma-glutaminkoncentrationen. Det fanns ett signifikant samband, 
patienter med lägre glutaminkoncentration hade en lägre produktion. Därmed kan det vara så 
att vissa patienter har en otillräcklig egen produktion och dessa kan gynnas av extra tillförsel 
av glutamin. 
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Studie II: I en tidigare, stor skandinavisk glutaminstudie randomiserades 
intensivvårdspatienter till att få intravenöst glutamintillskott eller placebo under hela IVA-
vistelsen. De som fick glutamin hade en minskad dödlighet på IVA, men efter sex månader 
såg man inte längre någon skillnad mellan grupperna. Två frågor uppstod; (i) utvecklade 
patienterna låg glutaminkoncentration när de lämnade IVA och glutamintillförseln avbröts, 
och (ii) fanns det ett samband mellan plasma-glutaminkoncentration efter IVA och dödlighet? 
Patienter som fått glutamintillförsel på IVA studerades därför, och resultaten var att (i) IVA-
överlevarna hade normala glutaminkoncentrationer, även utan tillskott, och (ii) 
glutaminkoncentrationen efter IVA hade inget samband med dödlighet. 
 
Studie III och V: Dessa två studier fokuserade på hög plasma-glutaminkoncentration. 
Eftersom det fanns en känd, men relativt outforskad, koppling mellan höga 
glutaminkoncentrationer och leversvikt så studerades fyra typer av leversvikt (studie III); 
kronisk leversvikt, akut-på-kronisk leversvikt, akut leversvikt och leversvikt efter omfattande 
leverkirurgi. Alla grupper hade individer med hög glutaminkoncentration, men det var 
betydligt vanligare i de två grupperna med akut svikt. Det fanns också en signifikant koppling 
till graden av leversvikt, ju mer avancerad svikt, desto större förekomst av hög 
glutaminkoncentration. 
 
I studie V mättes plasma-glutaminkoncentrationen vid ankomst till IVA på 269 patienter. Av 
dessa hade 26 hög glutaminkoncentration och i den gruppen dog 46% inom sex månader, 
jämfört med 18% för resterande patienter. Merparten av patienterna med hög 
glutaminkoncentration hade akut leverpåverkan och/eller känd leversjukdom, men det 
förekom även hos patienter utan leverpåverkan. För patienter som kom till IVA för eftervård 
efter en levertransplantation var överlevnaden efter sex månader emellertid 100% oavsett om 
de hade hög glutaminkoncentration eller inte. Sannolikt beror detta på att den nya levern 
snabbt kan återställa balansen hos dessa patienter. Om de levertransplanterade patienterna 
exkluderades var dödligheten efter sex månader 63% i gruppen med hög 
glutaminkoncentration. Dock är det ingenting som tyder på att de höga 
glutaminkoncentrationerna i sig är giftiga. De verkar snarare vara en markör för en kraftig 
påverkan av ämnesomsättningen, som vittnar om mycket avancerad sjukdom där förloppet är 
svårt att vända. 
 
Glutaminets roll vid intensivvårdskrävande sjukdom är fortfarande inte klarlagd. Eftersom 
låga plasmakoncentrationer uppträder tillsammans med en lägre kroppsegen produktion är det 
möjligt att det finns en grupp kritiskt sjuka patienter med en relativ glutaminbrist. Dessa 
skulle kunna dra nytta av extra glutamintillskott. Dessutom finns det bara en studie där 
glutamintillskott till intensivvårdspatienter visar negativa effekter. Det är otillfredsställande 
att mekanismen bakom detta resultat inte har kunnat förklaras. Därför är det viktigt att 
glutaminomsättningen i samband med kritisk sjukdom klarläggs ytterligare. 
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